Comprehensive Support for UK Bioscience Business

Latest:

OBN is a not-for-profit business network which provides comprehensive support for biotech and medtech companies in the Oxford and South-East England biocluster and beyond, providing networking, partnering, and group purchasing. Find out more about BioTrinity 2011 - our huge Biopartnering and Investment Conference, about OBN and download the OBN BioCluster Report 2011 or OBN BioCluster Map 2011.

Follow OBN on Twitter

Follow OBN on LinkedIn

	EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma- 02 Feb 2012
	Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases- 01 Feb 2012 Partnership in DNA-binding technology has potential to provide both companies growth through innovation of new therapies for people with serious diseases
	Physiomics to enter new therapeutic area with appointment of SAB member- 31 Jan 2012
	Vertex announces FDA Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis- 31 Jan 2012

	16 Feb 2012 - OBN BioThursday: Medtech Showcase - Updates and Upstarts
	16 Feb 2012 - Workshop - Delivering Memorable Presentations
	16 Feb 2012 - Workshop - Developing our Negotiation Skills
	28 Feb 2012 - BioTuesday: M&As : The Good the Bad and the Ugly
	13 Mar 2012 - BioTuesday: Innovative ways of getting your offer to large pharma

	08 Feb 2012 - Oxbridge Biotechnology Roundtable: Isis Innovation – commercialising Oxford University research
	09 Feb 2012 - Oxbridge Biotechnology Roundtable: How IP turns scientific breakthroughs into profitable ventures
	11 Feb 2012 - Oxbridge Biotechnology Roundtable: Start-up weekend